Align Technology, Inc. $ALGN Shares Bought by Grantham Mayo Van Otterloo & Co. LLC

Grantham Mayo Van Otterloo & Co. LLC grew its stake in Align Technology, Inc. (NASDAQ:ALGN) by 252.6% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 21,125 shares of the medical equipment provider’s stock after buying an additional 15,133 shares during the quarter. Grantham Mayo Van Otterloo & Co. LLC’s holdings in Align Technology were worth $2,645,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Sentry Investment Management LLC raised its holdings in Align Technology by 73.1% in the third quarter. Sentry Investment Management LLC now owns 187 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 79 shares in the last quarter. Steigerwald Gordon & Koch Inc. acquired a new position in Align Technology during the 3rd quarter worth approximately $26,000. Rothschild Investment LLC increased its position in shares of Align Technology by 140.3% in the 2nd quarter. Rothschild Investment LLC now owns 149 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 87 shares during the last quarter. Quent Capital LLC purchased a new stake in shares of Align Technology in the 3rd quarter valued at approximately $30,000. Finally, TD Private Client Wealth LLC raised its holdings in shares of Align Technology by 135.6% in the 3rd quarter. TD Private Client Wealth LLC now owns 238 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 137 shares in the last quarter. 88.43% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on ALGN shares. UBS Group lifted their price objective on shares of Align Technology from $175.00 to $185.00 and gave the stock a “neutral” rating in a research report on Thursday, February 5th. Stifel Nicolaus increased their target price on Align Technology from $200.00 to $210.00 and gave the company a “buy” rating in a report on Thursday, February 5th. Jefferies Financial Group raised their price target on Align Technology from $155.00 to $185.00 and gave the company a “hold” rating in a research note on Thursday, February 5th. Morgan Stanley lifted their price target on Align Technology from $154.00 to $169.00 and gave the stock an “equal weight” rating in a report on Thursday, February 5th. Finally, Mizuho upped their price objective on Align Technology from $200.00 to $215.00 and gave the stock an “outperform” rating in a research report on Thursday, February 5th. Six equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, Align Technology currently has an average rating of “Hold” and an average price target of $198.08.

Align Technology Price Performance

NASDAQ ALGN opened at $169.43 on Wednesday. The firm’s fifty day moving average price is $175.21 and its 200 day moving average price is $152.79. The company has a market capitalization of $12.08 billion, a price-to-earnings ratio of 29.93, a price-to-earnings-growth ratio of 1.91 and a beta of 1.79. Align Technology, Inc. has a 12 month low of $122.00 and a 12 month high of $208.30.

Align Technology (NASDAQ:ALGN) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $3.29 earnings per share for the quarter, beating analysts’ consensus estimates of $2.99 by $0.30. Align Technology had a net margin of 10.17% and a return on equity of 15.16%. The firm had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.03 billion. During the same period in the previous year, the company earned $2.44 earnings per share. Align Technology’s quarterly revenue was up 5.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Align Technology, Inc. will post 7.98 earnings per share for the current year.

Insider Activity at Align Technology

In other news, EVP John Morici sold 7,969 shares of the business’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $189.31, for a total value of $1,508,611.39. Following the completion of the sale, the executive vice president directly owned 8,237 shares of the company’s stock, valued at approximately $1,559,346.47. The trade was a 49.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.66% of the company’s stock.

Align Technology Profile

Align Technology, Inc (NASDAQ: ALGN) pioneered the use of digital technology in orthodontics through the development of the Invisalign system, a series of clear, removable aligners that provide an alternative to traditional metal braces. Since its founding in 1997 by Zia Chishti and Kelsey Wirth, the Tempe, Arizona–based company has expanded its focus to include intraoral scanners, CAD/CAM software for dental laboratories and comprehensive digital dentistry solutions.

The company’s signature Invisalign system leverages 3D imaging and computer-aided design (CAD) to create customized aligners that gradually reposition teeth, improving patient comfort and treatment predictability.